Cartrophen Vet : The disease modifying osteoarthritis drug longest on the market

osteoarthritis treatment for dogs

This article is sponsored content brought to you by Biopharm Australia.

Exciting News 

Biopharm Australia pioneered the veterinary development of sodium pentosan polysulfate as a disease modifying osteoarthritis drug (DMOAD) under the well-known name CARTROPHEN VET. 

We are a world leader in osteoarthritis treatment with high standard of safety and efficacy. Our products are acknowledged internationally, being approved as veterinary medicines by regulatory authorities around the world in more than 22 countries, where other disease modifying osteoarthritis drug have failed to obtain registration. 


Biopharm heavily invests in the development of new technologies and employee training. Three members of staff – Íde Kennedy, Conor Nolan and Vivek Bewley— have completed a course in Pharmaceutical and Medical Devices Development. David Cullis-Hill, the Managing Director, has also a Masters in pharmaceutical manufacturing technology. 

Our Facility 

We have a state of the art microbiological testing facility. This allows us to perform all microbiological tests involved in the manufacturing of our products. This will mean a faster turnaround time and a greater reliability on the results. Some of the tests we will be carrying out are Total Aerobic Microbial Counts, Total Yeast & Mould Counts, Pharmaceutical Waters, Bioburden Integrity Testing and Sterility Testing. The testing will be conducted according to British, European and US pharmacopoeias. 

For more information 

Call: 02 9389 0000

Email: or


Vet Practice magazine and its associated website is published by Engage Media. All material is protected by copyright and may not be reproduced in any form without prior written permission. Explore how our content marketing agency can help grow your business at Engage Content or at


Please enter your comment!
Please enter your name here